

Aralast™ NP, Glassia™, Prolastin-C®, and Zemaira® (alpha₁-proteinase inhibitor [human])



When requesting Aralast NP, Glassia, Prolastin-C, and Zemaira (alpha₁-proteinase inhibitor [human]), the individual requiring treatment must be diagnosed with an FDA-approved indication or approved compendial use and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved Indication

Aralast NP, Glassia, Prolastin-C and Zemaira are alpha₁-proteinase inhibitors indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe congenital deficiency of alpha₁-antitrypsin (AAT) deficiency.

Approved Off-label Compendial Use

Panniculitis due to alpha₁-antitrypsin (AAT) deficiency

Coverage Guidelines

Emphysema due to AAT deficiency

The individual must meet **all** of the following criteria for authorization:

- Is 18 years of age or older;
- Has a baseline (pretreatment) AAT serum concentration less than 11 micromol/L (less than 80 mg/dL); AND
- Is currently a nonsmoker.

Panniculitis due to AAT deficiency

The individual must be 18 years of age or older for authorization.

Approval duration: 12 months

Dosing Recommendation

The recommended dose is 60 mg/kg administered once weekly by intravenous infusion.

References

1. Aralast NP® [prescribing information]. Lexington, MA: Shire; December 2018.
2. Zemaira® [prescribing information]. Kankakee, IL: CSL Behring; April 2019.
3. Prolastin®-C [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; June 2018.
4. Prolastin®-C Liquid [prescribing information]. Research Triangle Park, NC: Grifols Therapeutics; August 2018.
5. Glassia® [prescribing information]. Lexington, MA: Shire; June 2017.
6. Brantly ML, Lascano JE, Shahmohammadi A. Intravenous alpha-1 antitrypsin therapy for alpha-1 antitrypsin deficiency: the current state of the evidence. *Chronc Obstr Pulm Dis*. 2018;6(1):100-114.
7. American Thoracic Society and the European Respiratory Society. Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. *Am J Respir Crit Care Med*. 2003;168:818-900.
8. Miravittles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in alpha1-antitrypsin deficiency. *Eur Respir J*. 2017;50(5).
9. Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: A Canadian Thoracic Society clinical practice guideline. *Can Respir J*. 2012;19:109-116.
10. Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. *Chronic Obstr Pulm Dis*. 2016;3(3):668-682.
11. Chowdhury MMU, Williams EJ, Morris JS, et al. Severe panniculitis caused by homozygous ZZ α_1 -antitrypsin deficiency treated successfully with human purified enzyme (Prolastin®). *Br J Dermatol*. 2002;147:1258-1261.
12. Ortiz P, Skov B, Benfeldt E. Alpha-antitrypsin deficiency-associated panniculitis: case report and review of treatment options. *J Eur Acad Dermatol Venereol*. 2005;19(4):487-490.
13. Geraminejad P, DeBloom JR, Walling HW, et al. Alpha-1-antitrypsin associated panniculitis: the MS variant. *J Am Acad Dermatol*. 2004;51(4):645-655.
14. Kjus T, Lutzow-Holm C, Christensen OB. Treatment of panniculitis associated with alpha-1-antitrypsin deficiency with alpha-1-protease inhibitor. *Acta Derm Venereol*. 2003;83(6):462-463.
15. Valverde R, Rosales B, Ortiz-de Frutos FJ, et al. Alpha-1-antitrypsin deficiency panniculitis. *Dermatol Clin*. 2008;26:447-451.
16. Lyon MJ. Metabolic panniculitis: alpha-1 antitrypsin deficiency panniculitis and pancreatic panniculitis. *Dermatol Ther*. 2010;23:368-374.
17. Olson JM, Moore EC, Valasek MA, et al. Panniculitis in alpha-1 antitrypsin deficiency treated with enzyme replacement. *J Am Acad Dermatol*. 2012;66:e139-e141.
18. Elsensohn AN, Curtis JA, Secrest AM, et al. Alpha-1-antitrypsin deficiency panniculitis presenting with severe anasarca, pulmonary embolus and hypogammaglobulinaemia. *Br J Dermatol*. 2015;173:288-314.
19. Elsensohn AN, Liaqat M, Powell G, et al. Alpha-1-antitrypsin associated panniculitis and corneal ulcer with a rare allelic variant (PiFZ): a case report. *Int J Dermatol*. 2015, October 16 [Epub ahead of Print].
20. Sabbagh DK, Barmayehvar B, Nguyen T, Edgar RG, Turner AM. Managing panniculitis in alpha-1 antitrypsin deficiency: systematic review of evidence behind treatment. *World J Dermatol*. 2018;7(1):1-8.
21. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2020. Available at: <https://goldcopd.org/gold-reports/>. Accessed on October 19, 2020.
22. Griesse M, Latzin P, Kappler M, et al. Alpha₁-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. *Eur Respir J*. 2007;29(2):240-250.
23. Martin SL, Downey D, Bilton D, et al, on behalf of the Recombinant AAT CF Study Team. Safety and efficacy of recombinant alpha₁-antitrypsin therapy in cystic fibrosis. *Pediatr Pulmonol*. 2006;41:177-183.